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Background: Given the increasing prevalence of diabetes and the lack of patients reaching recommended
therapeutic goals, novel models of team-based care are emerging. These teams typically include a combination of
physicians, nurses, case managers, pharmacists, and community-based peer health promoters (HPs). Recent
evidence supports the role of pharmacists in diabetes management to improve glycemic control, as they offer
expertise in medication management with the ability to collaboratively intensify therapy. However, few studies of
pharmacy-based models of care have focused on low income, minority populations that are most in need of
intervention. Alternatively, HP interventions have focused largely upon low income minority groups, addressing
their unique psychosocial and environmental challenges in diabetes self-care. This study will evaluate the impact of
HPs as a complement to pharmacist management in a randomized controlled trial.
Methods/Design: The primary aim of this randomized trial is to evaluate the effectiveness of clinical pharmacists
and HPs on diabetes behaviors (including healthy eating, physical activity, and medication adherence), hemoglobin
A1c, blood pressure, and LDL-cholesterol levels. A total of 300 minority patients with uncontrolled diabetes from
the University of Illinois Medical Center ambulatory network in Chicago will be randomized to either pharmacist
management alone, or pharmacist management plus HP support. After one year, the pharmacist-only group will be
intensified by the addition of HP support and maintenance will be assessed by phasing out HP support from the
pharmacist plus HP group (crossover design). Outcomes will be evaluated at baseline, 6, 12, and 24 months. In
addition, program and healthcare utilization data will be incorporated into cost and cost-effectiveness evaluations
of pharmacist management with and without HP support.
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Discussion: The study will evaluate an innovative, integrated approach to chronic disease management in
minorities with poorly controlled diabetes. The approach is comprised of clinic-based pharmacists and
community-based health promoters collaborating together. They will target patient-level factors (e.g., lack of
adherence to lifestyle modification and medications) and provider-level factors (e.g., clinical inertia) that contribute
to poor clinical outcomes in diabetes. Importantly, the study design and analytic approach will help determine the
differential and combined impact of adherence to lifestyle changes, medication, and intensification on clinical
outcomes.
Trial registration: ClinicalTrials.gov identifier: NCT01498159
Keywords: (3–10): Diabetes mellitus/drug therapy, Patient compliance, Patient education, Pharmacists, Community
health workersBackground
Individuals with diabetes are at greater risk for cardio-
vascular disease, the leading cause of death among men
and women [1]. To reduce the risk of cardiovascular dis-
ease, attentive management of blood glucose, blood
pressure, and LDL-cholesterol levels is paramount. Des-
pite available treatments, less than 10-20% of people
achieve their goals in therapy [2-7]. While time-trend
analyses show improvement in blood glucose, blood
pressure, and cholesterol control, African-Americans
and Latinos have worse control of these risk factors
compared with Whites [8-13]. These differences in inter-
mediate factors may contribute to higher complication
rates in minority groups, such as renal disease, coronary
artery disease, and amputations, as well as mortality
[9,14,15].
In order for most individuals to reach their goals in
therapy, regular, ongoing adherence to medication is
required. Common factors that contribute to non-
adherence include low health literacy, depression, lack of
medication knowledge, lack of social support, concerns
about adverse events and dependency, poor patient-
clinician communication, and limited access to health-
care resources [16,17]. In the Latino population, add-
itional barriers may include low English proficiency,
cultural issues, and poorer access to conventional
healthcare. Additionally, low adherence may reduce
treatment modifications and intensification [18,19].
From the healthcare provider perspective, intensifica-
tion of medication therapy is often limited by “clinical
inertia,” which occurs when providers fail to appropri-
ately intensify therapy in patients despite recognizing
elevations in blood glucose, blood pressure, or choles-
terol [20]. Clinical inertia is sometimes related to provi-
ders having limited time allotted for each encounter and
patients presenting with concerns that compete for at-
tention [20]. In addition, providers are often not trained
in the complex array of psychosocial or environmental
factors that affect adherence which must be addressed
prior to intensification of medication [21].Given the increasing prevalence of diabetes and the
lack of patients reaching recommended therapeutic
goals, novel models of team-based care are emerging.
These teams typically include physicians, nurses, case
managers, pharmacists, and community-based peer
health promoters (HPs) [17,22-24]. Recent evidence sup-
ports the role of office-based clinical pharmacists in dia-
betes management to improve glycemic control, as they
offer expertise in medication management with the abil-
ity to collaboratively intensify therapy [25-27]. Such
pharmacists are often found in primary care teams pro-
viding diabetes management [28,29].
Community-based health promoters may further en-
hance the effectiveness of clinical pharmacists in medi-
cation management [17]. Health promoter interventions
have focused largely upon low income minority groups,
addressing their unique psychosocial and environmental
challenges in diabetes self-care. Health promoters can
perform home visits and telephone calls to provide edu-
cation, evaluate medication use, promote behavioral
change and self-management, and reinforce pharmacist
and other provider recommendations. Such measures
may improve medication adherence and support intensi-
fication to reach goals in blood sugar, blood pressure,
and cholesterol.
Building upon a pilot study, the present study was
designed to determine the effectiveness of pharmacist-
health promoter team management in addressing medi-
cation adherence and intensification [17]. In addition,
the study will investigate the benefit derived from adding
HP support following receipt of clinical pharmacist ser-
vices, and maintenance of improved behaviors and out-
comes after phasing out health promoter support.




Our primary goal is to evaluate the effectiveness of
pharmacist plus health promoter support (Pharmacist
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diabetes behaviors (including healthy eating, physical ac-
tivity, and medication adherence), hemoglobin A1c, blood
pressure, and LDL-cholesterol levels among African-
American and Latino adults with uncontrolled type 2 dia-
betes. Secondarily, we will evaluate the maintenance of
improved diabetes behaviors, as well as clinical outcomes,
by phasing out health promoter support from the
Pharmacist+HP group after one year. Also, we will evalu-
ate the intensification offered by adding a health promoter
after one year of Pharmacist alone. Finally, we will deter-
mine the cost and cost-effectiveness of the Pharmacist
+HP and Pharmacist alone approaches.
Study design
The proposed study is a randomized trial with crossover
after one year (Figure 1). Three hundred African-
American and Latino patients with uncontrolled type 2
diabetes will be randomized to receive either:
1. Pharmacist: Clinical pharmacists will provide
medication and disease management services to
patients following a Pharmacist Management
Protocol.
2. Pharmacist+HP: Includes clinical pharmacist services,
plus a health promoter who will attend to both lifestyle
and medication adherence-related issues by identifying
barriers, solving problems, and providing support
through home visits and telephone contact.
After one year, groups will crossover. The Pharmacist
























Figure 1 Study Design. The proposed study is a randomized trial
with crossover after one year. Three hundred African-American and
Latino patients with uncontrolled type 2 diabetes will be
randomized to receive either Pharmacist or Pharmacist+HP
conditions. After one year, groups will crossover. The Pharmacist
group will be intensified by adding health promoter support.
Concurrently, maintenance will be evaluated in the Pharmacist+HP
group by phasing out health promoter support.support. Concurrently, maintenance will be evaluated in
the Pharmacist+HP group by phasing out health promoter
support. Outcomes in terms of medication adherence,
A1c, blood pressure, and LDL-cholesterol levels will be
evaluated at 0, 6-, 12- and 24-months.
Ethics
The research protocol has been approved by the Univer-
sity of Illinois at Chicago Institutional Review Board
(2011–0099).
Study population and site
The University of Illinois Medical Center (UIMC)
includes both inpatient and outpatient facilities serving a
diverse, low-income population in Chicago. There are
approximately 8,000 unique African American or Latino
individuals receiving care for diabetes in the outpatient
setting annually. The UIMC has multiple off-site ambu-
latory centers staffed by Family Practice and Internal
Medicine primary care physicians (PCPs), and include
affiliated Federally Qualified Health Centers (FQHCs).
We anticipate participation of 6–8 clinical entities in the
study. All sites share access to the electronic medical
record (EMR), Cerner Powerchart (Cerner Corporation,
Kansas City, MO).
Inclusion criteria
Patients will be eligible for the study if they: (a) are self-
identified as Latino/Hispanic or African-American; (b)
have verbal fluency in English or Spanish; (c) are age 21
or above; (d) have a history of type 2 diabetes; (e) have
an elevated A1c level 8% or higher in the past year
(confirmed through EMR); (f ) received primary care at
UIMC for at least one year; and (g) take at least one oral
medication for diabetes or hypertension (for adherence
assessment).
Exclusion criteria
Patients will be excluded from the study if they: (a) are
unable to verbalize comprehension of study or have
evidence of impaired decision making (e.g., dementia);
(b) live outside of the Chicago area three or more
months of the year; (c) have a household member
already participating in same study; (d) plan to move
from the Chicago area within the next year; or (e) are
pregnant or trying to become pregnant.
Identification, recruitment, and randomization of
participants
The recruitment process will be carried out separately
for each ambulatory site as determined by the project
coordinator and clinical staff. On-site research assistants
(RAs) will receive referrals from staff or patients inter-
ested in being screened for the study. All participant
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ensure A1c eligibility. Individuals deemed eligible will be
scheduled for an appointment at the university Clinical
Interface Core facility to complete written consent,
HIPAA authorization, and baseline data collection. The
RAs will inform patients that the research is being con-
ducted to improve medication management in diabetes
care and to find out whether pharmacists and health pro-
moters help people reach goals of therapy. The RAs will
spend additional time discussing the study protocol in
detail as part of consent procedures and use the “teach-
back” method to ensure participant comprehension [30].
Randomization to receive either Pharmacist or Pharma-
cist+HP assignments for the first year will occur after con-
sent and completion of all baseline data collection. A
random sequence of 300 participant assignments will be
used. Blocked randomization will ensure that allocation to
experimental conditions will be balanced within four
gender by ethnicity subgroups at each site. The project
coordinator will independently determine group assign-
ments and will log the information separately. Baseline
results for A1c and fasting lipid profile are entered into
the patient’s medical record by a study physician and elec-
tronically shared with the primary care physician and
pharmacist.
Sample size calculation
Sample size calculations are powered to detect change in
A1c. Based on a previous study [31], we estimated a
mean baseline A1c level of 10.0% with standard devi-
ation of 1.8% and an effect size of (1.0/1.8) 0.56. The
cross-time correlation was estimated to be 0.30. We
adjusted for clustering, assuming an intraclass correl-
ation coefficient (ICC) of 0.02 and cluster size of 30,
which yields a design effect of 1.58. Two-sided alpha of
0.05 and 80% power are assumed requiring a minimum
of 114 per group. Allowing for an estimated 10% drop-
out during each of the two years, approximately 150
patients will be required for each group (or 300 total).
Data analyses
Data will be analyzed for clinical effectiveness using
intention-to-treat principles [32-34]. To represent drop-
outs in the analysis, missing data will be imputed using
various approaches, such as “last value carried forward.”
The Little and Yau “return to baseline” imputation rule,
in which any gains over baseline levels dissipate upon
dropout, will be used for primary analyses. Patients who
share a single primary care physician (PCP) or health
promoter (HP), might exhibit similarities that are not
shared with patients attended to by other physicians. To
address this, we will include random effects in the model
for clinic site, PCP, and HP. We will include as predic-
tors relevant care and treatment-related variability suchas medication therapy intensifications and clinical en-
counter frequency.
We will test the hypothesis that A1c, blood pressure,
and LDL-cholesterol levels will be lower and diabetes
behaviors (including medication adherence) will be
improved with patients receiving Pharmacist+HP com-
pared with those receiving Pharmacist alone. Univariate
comparisons between the two study groups with respect
to outcome measures and covariates at baseline will be
conducted using Chi-square tests for categorical vari-
ables, Kruskal-Wallis tests for ordinal variables, and lin-
ear mixed models for continuous variables. Non-normal
continuous data will be transformed prior to linear
model analyses. The baseline variables include demo-
graphic, therapy complexity, and health literacy data. If
we find any between-group differences at baseline, we
will adjust for this in our primary multivariate analyses
by including relevant covariates.
We will also extend the usual analysis of crossover
designs by including a longitudinal trend component in
the first year. Thus, we can examine the time course (0,
6, and 12 months) as linear or quadratic over the first
three measurements. This will allow us to investigate
whether changes are made early, and at what rate they
continue through the rest of the time period. This ana-
lysis permits the comparison of trends between Pharma-
cist and Pharmacist+HP conditions. In addition, we will
regard participants as a random effect and will use
Gaussian mixed-model estimations (SPSS MIXED com-
mand). We can then substitute treatment by period
interactions for the carry-over effects, and the model
can be reduced in a recommended sequence (first omit
carry-over, then omit treatment, finally omit period).
The primary analysis of each outcome in the repeated
measures design will be conducted in a general linear
mixed model framework. In addition, SPSS MANOVA
(for repeated measures) will be used to explore the sim-
ultaneous impact of the treatment on multiple correlated
dependent variables, including the use of Roy-Bargmann
stepdown F-tests and discriminant function analysis as
post hoc tests to identify subsets of outcome measures
affected [35]. SPSS MIXED will be used to explore
patterned covariance structures such as compound sym-
metry and autoregression along with incorporating
time-varying covariates, such as depression. MANOVA
secondary analyses will explore the impact on results of
inhomogeneous baseline variables. Exploratory subgroup
analyses will determine which participants in the interven-
tion group had the greatest improvement in outcomes,
based on demographic factors, health literacy, and medi-
cation regimen. Group by time-trend interaction contrasts
also will be used to explore different group trajectories of
change. In addition, we will investigate the potential
consequences of medication intensification (e.g., initiation
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severe hypoglycemia.
We will explore diabetes-related behaviors (including
eating habits, physical activity, and medication adher-
ence) as well as medication treatment intensification as
alternative mediators using MPlus [36]. We will also test
the hypothesis that diabetes behaviors and clinical out-
comes will be maintained one year after phase-out of HP
support. Finally, we will test the hypothesis that diabetes
behaviors and clinical outcomes improved by adding HP
support after one year of Pharmacist alone.Pharmacists
Pharmacists will provide medication and disease man-
agement services to patients following an established
Pharmacist Management Protocol. In providing care,
pharmacist disease management services are comparable
to other disease management programs and include
comprehensive needs assessments, proactive health pro-
motion, patient-centric goals and education, interven-
tions to encourage behavioral change, and PCP support
and feedback [37]. The pharmacists will review current
medication use, identify therapeutic goals (particularly
A1c, blood pressure, and LDL cholesterol), formulate a
PCP-approved plan of care, and document the plan in
the EMR. Pharmacists will educate and encourage life-
style changes based upon ADA nutrition and physical
activity guidelines [38,39]. All patients recruited into this
study will require medication to control their diabetes.
The PCPs and pharmacists will decide on the algorithm
and approach to intensify therapy and how medication
changes may be made (based on national guidelines)
[40-42]. The intention is to establish optimal communi-
cation with minimal PCP burden (a similar approach to
our pilot study). Individual goals will be identified for each
participant for A1c, blood pressure, and LDL-cholesterol
(e.g., A1c ≤ 7%, blood pressure < 130/80 mm Hg, and
LDL < 100 mg/dL). In the proposed study, pharmacists
will adopt the ADA approach to individualized care,
where the general goal for non-pregnant adults is A1c less
than 7%. The pharmacists may decide upon less stringent
goals for those with a history of severe hypoglycemia, lim-
ited life expectancy, advanced micro- or macrovascular
disease, or extensive comorbid conditions [43].
Initially, the pharmacists will meet with patients to
reconcile medications and discuss therapeutic goals.
Next, the pharmacists will assess common barriers to
medication adherence including poor memory, lack of
diabetes knowledge, health beliefs, cost, medication bur-
den, physical disabilities, and social barriers. Following
the initial visit, encounters may occur in person, at the
clinic, or by phone. Duration between encounters may
increase based on individual preference and whenparticipants reach goals (with maximum of three
months). The pharmacist activities will include an evalu-
ation of adherence, medication reconciliation, and re-
view of home glucose and/or blood pressure monitoring
log data. Pharmacist education of patients will target
medication (name and purpose of medications; time,
strength, and method of administration); drug interac-
tions and side effects; goals of therapy; basic lifestyle
modifications; and use of pillbox, low-literacy medica-
tion lists, or other adherence aids.
Pharmacists will adjust therapy according to the plan
of care under PCP guidance and notify PCPs of agreed-
upon modifications via the EMR. Side effects identified
by the HP or pharmacist will be conveyed to the PCP
immediately and if the PCP is not available, the covering
clinic physician will be contacted per Pharmacist Man-
agement Protocol. Laboratory assessments including
electrolytes and renal function will be completed per
medication titration protocol. In addition to scheduled
study-related clinical data collection, point of care test-
ing will be performed during pharmacist visits as needed
based on guidelines to further guide treatment plans. For
hypoglycemia, pharmacists routinely monitor hypoglycemic
events, address prevention and review treatment. This
includes three steps: (1) addressing hypoglycemia with
every patient contact; (2) applying principles of aggressive
therapy (education, empowerment, frequent glucose self-
monitoring, flexible medication regimen, individualized
goals, professional guidance); and (3) considering risk
factors for hypoglycemia [44].
PCPs and clinical pharmacists are located in the same
medical center building. The pharmacists have direct ac-
cess to the PCP and routinely communicate in person, by
telephone, and by EMR messaging depending on urgency.
The pharmacist may adjust the medication regimen and
provider refills in accordance to the PCP-directed care
plan and response to therapy (to optimize blood glucose,
blood pressure, and cholesterol levels). All adjustments,
refills, and testing are completed under guidance of the
participants’ providers and updated in the EMR medica-
tion list. Pharmacists have access to participants’ full med-
ical records and can review flow-sheet and other chart
data including blood test results, clinical progress notes,
problem and medications lists, drug allergies, hospital-
ization records, and emergency room reports. Pharmacists
will forward all electronic progress notes to the PCP EMR
“Inbox” when medication changes are made. Progress
notes include a detailed list of medications, estimated ad-
herence levels, and home glucose and blood pressure
monitoring log information. However, for urgent medical
reasons, the PCP or covering provider will be contacted.
If, for any reason, the PCP feels that the patient should
not remain in the study, the provider can inform the PIs
to disenroll the participant.
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Health promoters conduct patient encounters, provide
medication and lifestyle adherence support and commu-
nicate with pharmacists. Each clinical site will work with
English- and Spanish-speaking health promoters (HPs)
who are each responsible for up to 25 participants. Can-
didates for HP positions will be identified through adver-
tisements, announcements, and organization meetings
targeting these contacts. HPs will have: (1) U.S. citizen-
ship; (2) a vehicle for transportation; (3) a bachelor’s
degree; and (4) excellent communication skills. HPs will
represent the communities being served.
All HPs will receive standardized training/re-training via
two educational curricula: (1) the Diabetes Empowerment
Education Program (DEEP) [45]; and (2) Training Cur-
riculum for Health Coaches [46]. DEEP uses an empower-
ment/autonomy framework. In addition, it includes adult
learning methodologies and interactive group exercises
with role-playing. The program trains HPs in increasing
patients’ knowledge, skills, and autonomy related to
diabetes management and control. The training addresses
physical activity, nutrition, psychosocial support, medica-
tion use, and the health care team interaction. The
Training Curriculum for Health Coaches, includes ses-
sions on the collaborative paradigm (ask instead of tell),
action plans, problem solving, cardiovascular disease and
medication management. HPs will also observe and
shadow pharmacists’ interactions with patients in the
UIMC Medication Therapy Management (MTM) Clinic
as an apprenticeship to gain insight into clinical pharma-
cists’ roles and activities, such as medication reconcili-
ation. Following training, we will assess HP competencies
in counseling and diabetes-related clinical skills. HPs are
video-recorded with standardized patients to provide
evaluation and feedback on coaching and empowerment
activities.
In addition, health promoter training will include time
to orient HPs to resources available to patients in the
medical facility (e.g., on-site pharmacy and social work-
ers). There will be time allocated for the HPs to tour the
medical campus to gain familiarity of the various clinical
sites where they could meet with participants individu-
ally or jointly with pharmacists. Other training experi-
ences include didactic sessions with a certified dietician
(with trips to a grocery store to review food labels and
compare products), clinical observations of health care
providers counseling on medication use, and independ-
ent learning through video and computer multimedia.
Periodic educational sessions are provided by specialists
from the medical center.
HP encounters will include home visits and telephone
contact. By performing home visits, the HPs may evaluate
home issues related to lifestyle changes (e.g., food inven-
tory), medication adherence (e.g., medication storage), andtechnique of injecting insulin and testing blood sugar. In
addition, the HPs will have glucose meters and automated
blood pressure home measurement devices to check blood
pressure and blood sugar. The HP encounter documenta-
tion will include duration of encounter, topics of discus-
sion, medications addressed, and need for pharmacist
communication. The HPs and pharmacists will communi-
cate in-person, by phone, or by secure e-mail to discuss
participant issues.
HPs will attend to medication adherence-related issues
by identifying barriers, solving problems, and providing
autonomy support. For example, HPs will address lan-
guage barriers with providers, limited health literacy,
transportation barriers, and cultural barriers (e.g., alter-
native therapy use that may interfere with or replace the
use of conventional medicines). HPs will attempt to elicit
and address concerns, beliefs, and social norms that may
threaten acceptance of and adherence to conventional
therapies. The HPs will parallel pharmacist activities by
evaluating adherence, assisting in medication reconcili-
ation, reviewing home glucose and blood pressure moni-
toring data, and providing reinforcement of proper
medication use. They will assist in the implementation
of pillbox use and other adherence aids as needed. Also,
HPs will have an iPad for participant use of multimedia
for education, skill building, and motivation (“Living
Well with Diabetes”) [31].
HPs will also provide education and support that
reinforce lifestyle adherence in conjunction with medica-
tion adherence. HPs are trained on the diabetic diet
along with basic physical activity recommendations so
that they can work with patients to set individual goals.
Education will address realistic and achievable food
choices, portion sizes, cooking preparation, relationships
between medications-meals-glucose levels, integration of
physical activity into lifestyle, and local community
resources for grocery shopping and physical activity.
Study measures
Control variables will be completed at baseline as follows.
Socio-demographic Data will include age, gender, self-
reported race and ethnicity, country of origin (if other than
U.S.), income, highest level of education, current employ-
ment status, marital status, number of adults and children
at home (and adults with diabetes), global health status
[47], and insurance. If the participant is Latino, data will
also include language spoken and thought in, provider lan-
guage spoken, and use of interpreter. Diabetes and Medical
History will include time since diabetes diagnosis, receipt of
diabetes education, home glucose monitoring frequency,
and self-reported provider visit frequency. Health Literacy
will be assessed using three items validated in English and
Spanish speaking populations [48]. ATransportation Survey
will assess barriers to visiting health care providers or a
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validation). Interpersonal Processes of Care, including com-
munication and other experiences with doctors and staff
members, will be assessed by the Interpersonal Processes of
Care Survey: Short Form (IPC-18).
Intermediate variables will be collected at four time
points (0, 6-, 12-, and 24-months). Diabetes Knowledge
will be assessed using the Spoken Knowledge in Low Lit-
eracy in Diabetes Scale (SKILL-D) (reliability .72) [49]. De-
pression will be measured using the 2-item Patient Health
Questionnaire (PHQ-2). Social Support will be measured
using a 4-item assessment of amount of total support
received and satisfaction of support from family, friends
and healthcare team [50]. Autonomous Self-Regulation will
be measured using 6-item Treatment Self-Regulation
Questionnaire (TSRQ, reliability 0.85-0.93) [51,52]. The
items begin with the stem, “The reason I would take my
diabetes and cholesterol medications exactly as prescribed
is. . .” Responses include ratings of reasons for taking med-
ications, such as, “. . .because I feel personally satisfied
when I keep my diabetes and cholesterol within strict
guidelines.” Perceived Competence will be measured using
the 4-item Perceived Competence Scale (PCS) to assess
patients’ experiences of feeling able to manage their dia-
betes successfully (reliability 0.80-0.94) [51,53,54]. Scores
are associated with quality of life, medication adherence,
and A1c [51,53].
HP Activity will be collected on a standardized work-
sheet completed after every participant contact (by phone
and in-person). Information obtained will include mode,
time, and content of contact, results of glucose or blood
pressure self-monitoring, goals, and interventions. Add-
itional information collected includes PCP and Pharma-
cist Activity and Medication Changes. The reconciled
medication list from the medical chart will be used as data
to evaluate medication changes and overall complexity of
therapy. Intensification of therapy will be defined as the
number of increases in the dosage of an antihypertensive
agent, hypoglycemic agent, or insulin, or the addition of a
new agent since the baseline visit [21]. Chart review will
define the number of PCP and pharmacist encounters as
well as the number of pharmacist- or physician-initiated
medication changes. Chart review will also include infor-
mation on actual medications prescribed for diabetes,
hypertension and hyperlipidemia, co-morbid conditions,
and diabetic complications.
Clinical Outcomes will be collected at four time points
(0, 6-, 12-, and 24-months). Professional research staff will
perform phlebotomy and measure blood pressure, weight
and height. These staff will be blinded to participant group
assignment. Hemoglobin A1c will be obtained via phlebot-
omy. The laboratory test has National Glycohemoglobin
Standardization Program certification. Fasting lipid pro-
files will also be obtained via phlebotomy, including HDL,LDL, and triglyceride measurements. Both A1c and lipid
profile results will be placed in the participant’s EMR.
Height and weight measurements will be obtained to de-
termine body mass index (BMI). A calibrated digital scale
will measure weight. A height stadiometer will measure
body height, with participants removing their shoes. Blood
pressure measurements will be recorded on participants
sitting down for at least five minutes, following standard
procedure.
Self-Care Behaviors related to diabetes self-management
including diet and physical activity will be evaluated
through the Summary of Diabetes Self-Care Activities
Measure (SDSCA) [55]. This includes 11 core items on
diet, exercise, blood sugar testing, foot care, and smoking.
Medication Adherence will be quantified using two meth-
ods. The Morisky Medication Adherence Scale will be
used to assess self-reported adherence for all participants.
The 8-item scale (reliability 0.83) will be completed once
for adherence to diabetes medication and once for hyper-
tensive medication, if applicable [56]. The second method
of adherence evaluation will consist of obtaining objective
pharmacy refill data. Each participant will provide contact
information for all of the pharmacies where prescrip-
tions have been filled for the past year. The HIPAA
authorization form allows research personnel to contact
the pharmacies for fill information. The personnel will
contact these pharmacies to collect information on the
prescriptions filled. For each prescription, the medication
name, date dispensed, dosage, frequency, quantity, and
days supply will be requested following an approach simi-
lar to that taken in a study on asthma [57]. The Propor-
tion of Days Covered (PDC), a measure of adherence, will
be calculated for all diabetes and hypertensive medications
using the prescription fill data obtained from pharmacies.
Health Related Quality of Life will be measured using the
Diabetes Distress Scale (DDS4) [58], a 4-item measure of
disease specific quality of life.
Cost and cost-effectiveness evaluation
We will conduct a cost-utility analysis comparing the
Pharmacist and Pharmacist+HP conditions, following the
guidelines for conducting pharmacoeconomic analyses
issued by the Panel on Cost-Effectiveness and Medicine
and the International Society for Pharmacoeconomics and
Outcomes Research [59-61]. We will conduct the analysis
from the health-system perspective, taking into account
direct program costs and direct non-program costs. Direct
program costs will include personnel, educational materi-
als, and any visit-related costs. Direct non-program costs
will include cost for all major health care utilization for
hospital admissions, emergency room visits, outpatient
visits and prescription medications during the interven-
tion period. Participants will complete an interview
regarding healthcare utilization outside of UIMC during
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visits and hospitalizations. For health care use received at
UIMC, hospital electronic records and billing data for
enrolled participants will be used to identify ambulatory
and hospital use, professional and technical visit fees,
emergency room visits, as well as laboratory and other an-
cillary services use. Cost estimates for the program costs
(salaries for HPs, etc.) will be based on prevailing costs
from appropriate published national sources, where pos-
sible. For example, healthcare use costs will be estimated
using national Medicare reimbursement rates (average
DRG rates) for hospitalization, Medicare fee schedules for
physician and other professional services, and Medicare’s
Resource-Based Relative Value Scale (RBRVS) for out-
patient procedures. Since our study will span a time
period exceeding one year, costs will be discounted using
a rate of 5% per year.
Our effectiveness measures will include improvements
in A1c, blood pressure, cholesterol levels and projected
quality-adjusted life-years (QALYs). The incremental cost-
effectiveness ratio (e.g., cost per change in A1c) of
Pharmacist+HP vs. Pharmacist alone will be estimated at
the end of 12 and 24 months. Cost per QALY will be
determined from projections of continued Pharmacist+HP
involvement and assumptions concerning the continued
effects of Pharmacist+HP on outcomes over time. The
QALY and utility estimates will be based on a Markov
model (CDC Diabetes Cost-effectiveness Group) [62].
Sensitivity analyses will estimate the impact of changes
in factors such as age, induced health-care visits, inci-
dence of complications, HP costs, physician time, and
discount rates.
Discussion
To our knowledge, this will be the first study to evaluate
the impact of HPs as a complement to clinical pharmacist
management in a randomized trial. The study incorpo-
rates evidence-based procedures of clinical pharmacists
and community HPs to assess their complementary in-
volvement in diabetes management.
The study design includes clinic-based pharmacists. We
chose to study pharmacists because the strongest empir-
ical support for improved diabetes medication manage-
ment currently lies in PCP-directed collaborative teams
with pharmacists. In fact, collaborative medication therapy
management by pharmacists has been approved in 46
states in the U.S. since 2008 for diabetes and dyslipide-
mia [63,64]. This growing level of pharmacist involve-
ment supports the need for further study of pharmacists
in team management as part of a patient-centered
medical home [65].
To complement pharmacist efforts in reaching minority
populations, we include HPs. Despite the endorsement of
peer HPs by the American Association of DiabetesEducators (AADE) and American Public Health Associ-
ation (APHA), they remain controversial in the U.S.
healthcare system [66-68]. Criticisms of HPs focus upon
the lack of formal evaluation studies supporting their ef-
fectiveness on clinical endpoints and weak connections
between HPs and providers. This study may provide
stronger evidence related to the benefits of HPs when they
are closely connected to clinic-based pharmacists.
While a number of studies have examined the impact
of HPs on diabetes management, there has been a
greater emphasis on lifestyle modification than on medi-
cation management. Pharmacists provide a unique re-
source for HPs with their expertise in medication
reconciliation, strategies to improve adherence, side
effects, and prescription fill management. HPs may be
less comfortable with the complexities of polypharmacy,
adjustments of medication dosages, and the evolving na-
ture of novel medication therapies utilized in diabetes
care. This research will help in understanding the sup-
port that pharmacists may provide to community HPs.
Important process data include the means by which
pharmacists and HPs communicate (by telephone, in-
person, or secure electronic mail).
A number of challenges and concerns have been con-
sidered. First, there may be significant variation in HP
attention and impact. To address this, health promoters
will be uniformly trained through a CDC-funded cur-
riculum. We include regular re-evaluation of activities to
detect drift. Health promoters will follow an established
protocol for patient contact; and will maintain a log to
be submitted to a supervisor for evaluation. Next, other
health care providers, including PCPs, may adjust ther-
apy independent of study procedures. Medical record
reviews will describe medication changes if completed
within the UIMC health care system (where it is
expected to most commonly occur). Analyses will in-
clude medication changes by pharmacist or other pro-
vider. Finally, while a majority of Latino patients are
Mexican-American in Chicago (~75%), others come
from Puerto Rico or elsewhere, and may have a different
cultural background. Health promoters are trained to be
sensitive to these differences, in cases where there may
be a mismatch between health promoter and client.
In conclusion, the study will evaluate an innovative,
integrated approach to chronic disease self-management
in minorities with poorly controlled diabetes. The ap-
proach is comprised of clinic-based pharmacists and
community-based health promoters collaborating to-
gether. Pharmacists and HPs will target patient-level
factors (i.e., lack of adherence to lifestyle modification and
medications) and provider-level factors (i.e., clinical iner-
tia) that contribute to poor clinical outcomes in diabetes.
Importantly, the study design and analytic approach will
help determine the differential and combined impact of
Gerber et al. BMC Public Health 2012, 12:891 Page 9 of 10
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tion on clinical outcomes.
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